Chiusura precedente | 2,0600 |
Aperto | 2,1200 |
Denaro | 2,0800 x 100 |
Lettera | 2,1000 x 3200 |
Min-Max giorno | 2,0350 - 2,2100 |
Intervallo di 52 settimane | 0,7000 - 3,4000 |
Volume | |
Media Volume | 6.086.261 |
Capitalizzazione | 393,954M |
Beta (5 anni mensile) | 0,82 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -2,0300 |
Prossima data utili | 07 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 7,41 |
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular d
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11, 2023 at 3:00 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investo
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk reduction in MACE-3 – – No increase in development of new onset diabetes in patients randomized to bempedoic acid compared to placebo – ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two o